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Abstract: Perinatal hypoxia-ischemia (HI) is an important cause of neonatal brain injury. Recent progress in the search 
for neuroprotective compounds has provided us with several promising drugs to reduce perinatal HI-induced brain injury. 
In the early stage (first 6 hours after birth) therapies are concentrated on prevention of the production of reactive oxygen 
species or free radicals (xanthine-oxidase-, nitric oxide synthase-, and prostaglandin inhibition), anti-inflammatory effects 
(erythropoietin, melatonin, Xenon) and anti-apoptotic interventions (nuclear factor kappa B- and c-jun N-terminal kinase 
inhibition); in a later stage stimulation of neurotrophic properties in the neonatal brain (erythropoietin, growth factors) can 
be targeted to promote neuronal and oligodendrocyte regeneration. Combination of pharmacological means of treatment 
with moderate hypothermia, which is accepted now as a meaningful therapy, is probably the next step in clinical treatment 
to fight post-asphyxial brain damage. Further studies should be directed at a more rational use of therapies by determining 
the optimal time and dose to inhibit the different potentially destructive molecular pathways or to enhance endogenous 
repair while at the same time avoiding adverse effects of the drugs used. 
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INTRODUCTION 
  Despite important progress in obstetric and neonatal care 
during the last decades, perinatal hypoxia-ischemia (HI) or 
birth asphyxia is still one of the most important causes of 
neonatal brain injury and the associated adverse develop- 
mental outcome [1, 2]. Currently, treatment options for post-
asphyxial reperfusion/reoxygenation injury of the brain are 
largely supportive with prompt recognition and treatment of 
seizures, normalization of blood glucose levels, optimizing 
blood gases and blood pressure [3]. Recently, experimental 
and clinical studies have shown that moderate hypothermia 
with a reduction of body temperature to 33-to-34 
OC, if 
started within the first 6 h after birth, provides moderate 
neuroprotection [4-7]. This therapy has now been accepted in 
clinical practice as a strategy to fight post-asphyxial brain 
damage [8]. It is conceivable that outcome can further 
improve when hypothermia is combined with other (pharma- 
cological) means of neuroprotection or with stimulation of 
regenerative processes in the neonatal brain. Damage due to 
perinatal HI in the premature infant is different from that in 
the full term newborn. In the premature infant, HI brain 
injury mainly involves pre-myelinating oligodendrocytes and 
white matter injury. However, this review will not discuss 
post-HI brain damage to the premature infant. 
  We will first summarize and briefly discuss the 
potentially destructive molecular pathways set in motion 
upon reperfusion and reoxygenation of the brain of the 
asphyxiated full-term neonate [9]. Subsequently, we will 
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describe which pharmacological interventions can be 
considered to inhibit these destructive pathways including 
the most optimal postnatal moment to do so.  
MOLECULAR MECHANISMS OF REPERFUSION 
INJURY TO THE BRAIN AFTER PERINATAL HI 
  Post-asphyxial reperfusion injury to the brain is caused 
by a cascade of molecular reactions as summarized below in 
order of their occurrence: 
1. Calcium Influx and Free Radical Formation 
  During HI, ATP formation is impaired due to hypoxia 
and immediately after reperfusion and reoxygenation 
reactive oxygen species are produced. Together, these pro- 
cesses cause an excessive influx of calcium stimulated by 
opening of voltage-regulated calcium channels which lead to 
release of neurotransmitters such as glutamate. Glutamate can 
activate receptor-regulated (N-methyl-D-aspartate [NMDA]) 
calcium channels thereby further increasing calcium. This 
triggers enhanced production of free radicals and activation 
of lipases, proteases, and endonucleases. As a consequence, 
releasing of free fatty acids, especially arachidonic acid, will 
activate cyclooxygenase and will catalyse the formation of pro-
staglandins which will liberate among other things super- 
oxide free radicals. In addition, formation of oxygen free radi-
cals is also enhanced via metabolizing hypoxanthine formed 
during the actual period of HI to uric acid. Collectively, these 
processes will lead to a surge of the superoxide free radical, 
which plays a central role in further production of free 
radicals and other toxic compounds, see also below [10-12].  
2. Free Iron Accumulation and Fenton Reaction 
  During the actual period of HI, protein-bound iron within 
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binding proteins, especially because of the low intracellular 
pH.Non-protein bound iron (NPBI) or free iron will 
accumulate, which is an important pro-radical. Upon reper- 
fusion and reoxygenation, NPBI will react with superoxide-
derived hydrogen peroxide (see above) to form the very toxic 
hydroxyl free radical, the so-called Fenton reaction [13]. 
NPBI has been related to excessive brain damage in the 
immediate post-HI period in both experimental [14] and 
clinical [15] studies.  
3. Nitric Oxide Synthases and Brain Injury 
  Nitric oxide (NO) is a free radical produced by nitric 
oxide synthases (NOS) that are expressed in the brain in 
neurons, astrocytes, and endothelial cells and can be induced 
in microglia. There are three isoforms of NOS [16]: 
endothelial or eNOS, neuronal or nNOS, which are 
constitutionally expressed forms of NOS that produce NO in 
moderate amounts in response to increased intracellular 
calcium. An inducible form or iNOS can also be expressed in 
the brain. eNOS is thought to have a neuroprotective 
function via enhancing perfusion of the brain if necessary 
[17]. Upon reperfusion and reoxygenation after perinatal HI, 
however, eNOS and nNOS are activated leading to excess 
production of NO. Moreover, in a later stage (see below), 
continuous production of NO occurs via  upregulation of 
iNOS in infiltrating neutrophils, macrophages and microglia. 
NO then can react with superoxide (see above) to form the 
toxic peroxynitrite which can contribute to further damage to 
brain tissue [18-21].  
4. Pro- and Anti-Inflammatory Activity 
  Three-to-12 hours after reperfusion and reoxygenation an 
inflammatory response, probably induced by excessive free 
radical production and high levels of extracellular glutamate, 
will be activated and pro- and anti-inflammatory cytokines 
such as TNF-, IL-1, IL-6, IL-8 and IL-10 are produced [22]. 
The activation of two transcription factors, i.e. Nuclear 
Factor kappa B (NFB) and c-Jun N-terminal kinase (JNK) 
play a central role in the post-HI inflammatory process. In 
addition, these transcription factors can regulate expression 
of pro- and anti-apoptotic proteins and thus can contribute to 
damage (see below) or neuroprotection [23-25].  
5. Apoptosis Activation 
  As indicated above, apoptotic activity contributes to 
brain damage in the neonate and is an important pathway  
in the process of delayed neuronal death [26]. Apoptosis   
is an energy-dependent process and ATP is required for 
apoptosome formation and subsequent caspase activation 
[27]. Caspases and especially the executioner caspase-3 are 
activated in this process and bring about most of the changes 
that characterize apoptotic cell death [28]. Activated 
caspase-3 is expressed at higher levels in the developing 
brain after perinatal HI, giving rise to the assumption that 
apoptotic mechanisms of neuronal cell death seem to be 
more important in neonatal brain injury compared to adults 
[29].  
6. Downregulation of Growth Factors 
  It has been proposed that inflammatory activity in the 
brain, together with the excessive production of toxic 
compounds like peroxynitrite and free radicals induce 
downregulation of the formation of neurotrophic factors and 
neurogenesis. Since the ability of the developing brain to 
recover after perinatal HI may well depend on production of 
neurotrophic and neurite-outgrowth promoting factors, 
downregulation of these growth factors may play an 
important role in delayed brain damage (up to several weeks) 
after perinatal HI [30].  
 Fig.  (1) shows proposed injuring mechanisms induced 
upon and after reperfusion / reoxygenation after perinatal 
hypoxia-ischemia. 
PHARMACOLOGICAL NEUROPROTECTIVE  
STRATEGIES 
  Based on the mechanisms of perinatal HI brain injury, 
current therapeutic studies mainly focus on the 
pharmacologic targets we mentioned above. Since moderate 
hypothermia is developing into a clinical therapy, studies to 
investigate the effect of pharmacological interventions in 
combination with hypothermia are now also initiated. These 
pharmacologic therapies can start at different points of time 
after the actual HI insults with or without hypothermia 
depending on to the mechanism of action (neuroprotection 
versus repair mechanisms). In addition, treatment with stem 
cells to enhance repair is a promising intervention [31, 32] to 
repair HI brain damage. 
1. Early Post-HI Period (up to 6 Hours after Reperfusion/ 
Reoxygenation) 
  The early post-HI period contains an important 
therapeutic window [33] and the main pharmacological inter- 
ventions are dependent on anti-oxidative, anti-inflammatory, 
and/or anti-apoptotic properties. 
Voltage-Regulated and Receptor-Regulated Ion Channel 
Blockers 
  Reduction of calcium influx into neuronal cells by 
blockage of voltage-regulated ion channels has extensively 
been investigated. Calcium blockers including nicardipine 
and flunarizine gave encouraging results in experimental 
studies [34, 35]. However, a clinical study with nicardipine 
in term neonates suffering from perinatal asphyxia had to be 
discontinued because of severe hypotension [36]. Blocking 
NMDA-receptors (i.e. glutamate regulated ion channels) 
with magnesium was investigated in clinical trials, but 
without beneficial effects and severe hemodynamic adverse 
effects were sometimes reported [37-39]. A recently 
advocated approach is the use of the gaseous anesthetic 
Xenon, which is thought to act as an NMDA-receptor 
antagonist. Experimental studies in newborn animals show 
efficient neuroprotection, especially when administered in 
combination with moderate hypothermia [40, 41]. A major 
disadvantage of this intervention is that Xenon is very 
expensive and administration is rather complicated, requiring 
intubation and ventilation of the patient, and a high 
percentage of Xenon thereby reducing the maximum FiO2.  
Anti-Oxidative Therapies 
  The production of superoxide, the superoxide-derived   
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to xanthine-oxidase, prostaglandin and NPBI production [42- 
44]. Allopurinol is a xanthine-oxidase inhibitor that at higher  
dosages is thought to chelate free iron molecules and to be a  
direct scavenger of hydroxyl radical [45]. This should be   
also true for oxypurinol, the even more efficient active   
metabolite of allopurinol [46]. Allopurinol was first   
recognized to have neuroprotective properties by Palmer et al.  
in a neonatal rat model of HI brain injury [47]. The data of  
this study were promising, although another study was   
less positive on the neuroprotective potential of allopurinol  
[33]. Human studies in asphyxiated term newborns are not  
very convincing concerning the neuroprotective effects of   
allopurinol and oxypurinol, showing at best a moderate   
reduction of free radical production. One study reported   
virtually no positive effect on neurodevelopmental outcome  
[48], whereas one study in asphyxiated term newborns   
reported an improvement of neurodevelopmental outcome   
after allopurinol treatment [49]. Most probably, in most   
clinical studies therapy is started too late to expect a   
reduction of xanthine-oxidase production [48]. A pilot study  
of our group on maternal allopurinol treatment in those   
mothers who were on the brink of delivery with fetal   
hypoxia, showed a reducing effect on biomarkers of neuronal  
damage and NPBI after allopurinol administration to the   
mother [50]. We are currently examining the effect of   
maternal allopurinol treatment on neonatal outcome in a   
similar set-up. 
  With respect to the pro-free radical properties of NPBI, 
several experimental studies have been performed in 
newborn animals of various species including pigs and rats 
with positive results [14, 51]. Up to now, however, free ion 
chelators, have never been tested in newborn babies to treat 
reperfusion/reoxygenation injury after perinatal HI.  
  Due to the toxic effects of excessive formation of NO 
free radical in the early reperfusion/reoxygenation phase, 
inhibition of NOS production may ameliorate perinatal brain 
damage after HI. Non-selective NOS inhibitors such as nitro-
L-arginine administered during the early post-HI period have 
been reported to reduce free radical-mediated reperfusion 
injury to the neonatal brain [52, 53]. However, an increasing 
number of studies showed that non-selective NOS inhibitors, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Possible injuring mechanisms induced upon and after reperfusion/ reoxygenation after perinatal hypoxia-ischemia. Reperfusion/ 
reoxygenation induces opening of ion channels which leads to influx of calcium into neurons and subsequent excessive neurotransmitters 
producing and activation of enzymatic reactions (1). The actions give rise to subsequent metabolisation of hypoxanthine, fatty acids 
originating from neuronal cell membranes, and of nitric oxide production and the Fenton reaction (2). This leads to excessive free radicals 
formation, lipidperoxidation and ultimate neuronal cell death. Somewhat later (6-12h after reperfusion/reoxygenation), the pro-inflammatory 
response occurs with activation of cytokines and iNOS production (3), leading to caspases activation (4), growth factor modulation (5) and 
apoptosis. JNK=c-Jun N-terminal kinase; NMDA= N-methyl-D-aspartate; NO= nitric oxide; NOS= nitric oxide synthase; eNOS= 
endothelial NOS; nNOS= neuronal NOS; iNOS=inducible NOS, NPBI=non-protein bound iron; NFB=Nuclear Factor kappa B; 
VRCC=voltage-regulated calcium channel. Pharmacological Neuroprotection after Perinatal Hypoxic-Ischemic  Current Neuropharmacology, 2010, Vol. 8, No. 4    327 
especially those with prominent inhibitory effects on eNOS, 
prevent adequate post-HI brain perfusion, eventually leading 
to increased production of free radicals and thus aggravating 
brain damage [54-56]. Selective inhibition of nNOS and 
iNOS with the nNOS inhibitor 7-nitroindazole and the iNOS 
inhibitor aminoguanidine proved to be more promising as a 
neuroprtective strategy as has been shown in several studies 
in neonatal rats [57-59]. The compound 2-iminobiotin (2-
IB), which has inhibitory effects on nNOS and iNOS in 
vitro, did have strong neuroprotective effects in a neonatal 
rat model of neonatal HI brain damage. Notably, however, 
only female and not male animals were protected against 
post-HI reperfusion damage to the brain [60, 61]. Moreover, 
the existing evidence suggests that the in vivo neuropro- 
tective effect of 2-iminobiotin was not dependent on nNOS/ 
iNOS inhibition [61, 62]. The exact mechanism of action of 
2-IB remains to be determined, but it is clear that in females 
neuroprotection by 2-IB is associated with reduced activation 
of apoptotic pathways.  
  Finally, prostaglandin inhibition has been another 
important target to fight post-HI brain damage in the 
newborn. Indomethacin, a cyclooxygenase inhibitor, has 
been shown to reduce neonatal brain damage after perinatal 
HI in experimental studies [63]. Although indomethacin is 
currently used in preterm babies to reduce or prevent the 
occurrence of periventricular/intraventricular hemorrhages 
[64, 65] and can reduce white matter injury in these tiny 
infants [66, 67], it has not been used yet in the term infant to 
reduce reperfusion/reoxygenation injury of the brain after 
perinatal HI.  
Anti-Inflammatory Therapies 
  As mentioned above, the inflammatory pathway is 
activated after perinatal HI and therefore anti-inflammatory 
strategies are another meaningful tool to fight reperfusion 
injury to the newborn brain.  
  Erythropoietin (EPO), which was first recognized as   
a humoral mediator involved in the maturation and 
proliferation of erythroid progenitor cells [68], has recently 
been recognized as a neuroprotective agent in the brain of a 
variety of mammals including humans [68-72]. Mostly 
recombinant Human EPO (rhEPO) has been used in these 
studies. One of the possible mechanisms of its neuro- 
protective effects is an anti-inflammatory effect after binding 
to its receptor (EPOR) which is expressed on several types of 
brain cells including astrocytes and microglial cells [73, 74]. 
Intraperitoneal and subcutaneous administration of EPO in 
newborn animals after HI improved neurobehavioral 
outcome [75, 76] and administration to humans also had 
neuroprotective effects [72]. Also negative results are 
reported in both clinical and experimental studies [77, 78]. 
Gender effects are also reported to contribute to the 
neuroprotective role of EPO. In a rat model of neonatal 
stroke, EPO reduced the infarct volume and improved long-
term behavioral outcome more significantly in females than 
in males [79]. An ongoing study in mice pups of our own 
group also suggests similar gender dependent neuropro- 
tection in females after neonatal HI (unpublished data, Fan  
et al.).  
  Melatonin, the major secretory product of the pineal 
gland, mainly mediates circadian rhythmicity and seasonality 
[80]. Recent studies reported that melatonin has a neuro- 
protective effect during perinatal HI-induced brain injury. 
Using a P7 rat HI model, it was shown that sensorimotor 
asymmetry and learning deficits were significantly reduced 
after administration of melatonin before or up to 10 min after 
HI [81]. Histologically, brain injury was significantly 
attenuated in the melatonin-treated group. In a fetal sheep 
model with umbilical cord occlusion, melatonin had anti-
inflammatory effects as it reduced microglial cell activation 
[82]. The anti-inflammatory effect of melatonin may be 
mediated by preventing the translocation of NF-B to the 
nucleus, thus reducing the upregulation of pro-inflammatory 
cytokines [83]. To date no human studies are known inves- 
tigating its neuroprotective effects after perinatal HI. 
  Moreover, our own recent studies have shown that 
treatment of neonatal rats after HI with etanercept, a soluble 
TNF- receptor functioning as a TNF- inhibitor, also has 
neuroprotective effects [84].  
Anti-Apoptotic Strategies 
  As we mentioned above, NFB is a ubiquitously 
expressed transcription factor that regulates expression of 
inflammatory genes and of genes involved in apoptosis. 
TAT-coupled (a method for transducing proteins into cells) 
NFB essential modulator Binding Domain (NBD)-peptide, 
a specific NFB inhibitor, was reported to rapidly distribute 
to the brain and inhibit cerebral NFB activation when 
administered intraperitoneally after neonatal HI in p7 rats. 
TAT-NBD treatment prevented upregulation of p53 and 
activation of caspase-3 after HI [23]. TAT-NBD treatment 
strongly reduced histological damage when administered 
within 6 h after HI. Our most recent data demonstrate that at 
this histological improvement was associated with restora- 
tion of sensorimotor and cognitive abnormalities. Sur- 
prisingly, NFB treatment did not reduce cerebral cytokine 
production despite the marked protective effects. Activation 
of the c-Jun N-terminal kinase (JNK) pathway is also 
involved in neonatal brain injury [25]. The specific JNK 
inhibitor TAT-JBD, which is the TAT coupled JNK binding 
domain of JNK-interacting protein-1 (also known as L-JNK-
I) also has neuroprotective effects. Recent studies reported 
that JBD improved both short term and long term 
histological and behavioral outcomes in neonatal rats after 
HI [84, 85]. Similar to what was observed for the NFB 
inhibitor, the protective effect of JBD occurred indepen- 
dently of inhibition of cytokine production [85]. Notably, 
prolonged inhibition of the JNK pathway as induced by 
administration of the D-isomer of JNK-I or of the NFB 
pathway by repeated administration of NBD at 0, 6 and 12h 
after HI did not improve outcome or even had some adverse 
effects [24, 86, 87].  
Hyperbaric Oxygen Therapy 
  The earliest insight into the therapeutic effect of 
hyperbaric oxygen (HBO) originated from the observation 
that HBO was capable of decreasing edema and necrosis in 
ischemic skeletal muscle [88]. Although the optimal 
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neonatal HI brain injury remains controversial [89], studies 
on the effect of HBO are still being carried out [90].   
In a P7 rat model, administration of HBO for 1h after   
HI significantly improved sensorimotor function during 
behavioral test and reduced the loss of brain volume [91]. 
The detailed mechanisms of neuroprotection by HBO are not 
clear yet. Existing studies indicated that neuroprotection was 
associated with reducing polymorphonuclear leukocytes 
(PMNL) adhesion [92], downregulating endothelial cell 
adhesion molecules (CAM) expression [93], inhibiting iNOS 
production while inducing eNOS production [93, 94], 
upregulating antioxidant enzyme activity [95] and improving 
cellular energetics [96]. Furthermore, HBO is capable of 
suppressing mitochondrial apoptotic pathways via reducing 
cytoplasm cytochrome c levels, decreasing caspase enzyme 
activity and upregulating the ratio of Bcl-2 (an anti-apoptotic 
gene) and Bax (a pro-apoptotic gene) expression [97]. HBO 
also contributes to brain cell proliferation [98]. In a P7 rat 
hypoxic-ischemic model, the treatment of HBO could be 
delayed until 12 h after HI, while the effect decreased 24 h 
after HI [99]. 
2. Treatment Modalities Later in the Post-HI Period 
  The intrinsic ability of the immature brain to reduce 
(post) HI-induced damage is also dependent on production of 
trophic factors and endogenous regenerative activity. In view 
of the capacity of the neonatal brain to repair damage, 
stimulation of endogenous repair processes has also been 
suggested as a possible intervention in neonatal HI-brain 
damage. 
Trophic Factor Therapy 
  Several trophic or growth factors have been examined in 
the context of neonatal HI brain injury: epidermal growth 
factor (EGF), insuline-like growth factor 1 (IGF-1) and brain-
derived neurotrophic factor (BDNF) among other factors   
are very important for the appropriate development of the 
developing brain [100]. Downregulation of the expression 
(neurotrophic) growth factors is thought to play a pivotal role 
in (delayed) damage to the brain of the neonate after 
perinatal HI. Suppletion of deficient growth factors may 
therefore reduce or prevent delayed HI-induced brain dam- 
age. Trophic factors also stimulate neurogenesis by activa- 
tion of the endogenous neural stem cells (NSC) residing in 
the subventricular zones and subgranular zone of the dentate 
gyrus, as shown in studies in rodent pups models [101, 102]. 
  EPO has, besides its anti-oxidative and anti-inflammatory 
effects [74, 103], also quite strong neurotrophic abilities as 
was shown in experimental animal and in vitro studies: a 17-
mer peptide sequence called epopeptide AB has been 
identified in the structure of EPO, and this peptide is 
considered to contain the neurotrophic properties [104]. In 
vitro this peptide can induce neural progenitor cell 
proliferation and prevents neuronal cell death [105]. In an 
adult rat stoke model, administration of EPO promoted 
neurogenesis in the subventricular zone via upregulation of 
BDNF expression [106]. By using embryonic a neural stem 
cell culture, studies showed that EPO enhanced formation of 
neurons [107]. In a P10 rat stroke model, EPO increased the 
percentage of newly generated neurons as well [108]. 
  Other neurotrophic factors have also been investigated. 
IGF-1, an anabolic pleiotrophic factor, is essential for 
postnatal brain development [109]. It has been shown that 
IGF-1 is induced in neonatal brain after HI [110]. In a P7 rat 
model, intranasal administration of IGF-1 improved 
neurobehavioral performance, inhibited apoptotic cell death, 
and enhanced proliferation of neuronal and oligodendroglial 
progenitor cells after HI [111]. Basic fibroblast growth factor 
(bFGF), a polypeptide growth factor, has been shown to 
prevent NMDA-induced neurotoxicity in neonatal rats after 
HI [112]. Continuous intracerebroventricular injection with 
BDNF resulted in an increased number of surviving neurons 
in P8 rat brains after HI [113]. An important role with 
respect to neurotrophic reduction and repair of brain damage 
has been supposed for hypoxia-induced-factor 1 (HIF-1), 
which will be activated during hypoxia-ischemia and gives 
rise to the production of a series of transcriptional targets, of 
which EPO and vascular endothelial growth factor (VEGF) 
are important ones with respect to brain repair [114-116]. 
  Neuronal stem cell transplantation is a potentially 
important therapy to reduce long-term brain damage after 
perinatal HI and have shown to improve motor- and 
behavioral outcome in adolescent and adult periods [31,   
117, 118]. It appears from these studies that NSC’s can 
differentiate into neurons and oligodendrocytes and stimulate 
angiogenesis [31, 119].  
  Recent evidence suggests that stroke or HI-induced 
global brain damage can also be treated with stem cells from 
other sources than brain, such as mesenchymal stem cells 
(MSCs) [120, 121]. MSCs can easily be obtained from the 
bone marrow of healthy adults, placental tissue, umbilical 
cord stroma (Wharton's Jelly) and even from cord blood. 
Since MSCs are hardly immunogenic, these cells can also be 
used for allogeneic transplantation. After administration in 
the brain, these MSCs can express neuronal markers like 
NeuN and MAP-2, the astroglial marker GFAP, the 
microglial marker IB4 [122, 123]. Furthermore, It is known 
that MSC secrete several trophic factors that are known to 
contribute to neuroprotection including, colony-stimulating 
factor-1, stem cell factor, VEGF, basic fibroblast growth 
factor (bFGF), nerve growth factor (NGF) and brain-derived 
neurotrophic factor (BDNF) [124, 125]. Notably, recent 
findings indicate that intracranial administration of MSC as 
late as 3-10 days after the HI insult reduces histological 
damage and improves sensorimotor outcome in both 
neonatal mouse and rat HI model [31, 117, 118]. We also 
showed that MSC treatment stimulated formation of new 
neurons and oligodendrocyte and that newly formed cells 
were not of transplant origin. These findings indicate that 
MSC treatment enhances endogenous repair mechanisms in 
the brain [32].  
3. Combination Therapy: More Effective than Single 
Therapy? 
  Although studies in rodents have identified many 
different molecular pathways as potential targets for 
neuroprotective strategies after perinatal HI, intervening in 
one particular pathway may not be sufficient to completely 
prevent brain injury because of the complex mechanisms of 
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one of the potentially destructive pathways, combinations of 
therapies intervening at different levels in the cascade might 
lead to more prominent reduction of brain injury.  
  There is already some evidence that pharmacolgoical 
interventions combined with hypothermia have a stronger 
neuroprotective effect after HI than either one alone [41, 
126]. Since it is conceivable that hypothermia postpones 
secondary energy failure, application of hypothermia 
immediately after the hypoxic event could prolong the 
window for pharmacotherapeutic intervention [6, 127]. In a 
P7 rat HI model, the hypothermia/Xenon combination 
conferred more protection as determined in behavioral tests 
and at the level of histology than either treatment alone [41]. 
In addition, protection was observed even when Xenon 
administration was delayed or applied for shorter period of 
time [128]. The hypothermia/EPO combination is used in 
out-of-hospital cardiac arrest and this combination can 
improve the survival rate in adults, but to date there are no 
data on combined EPO/hypothermia treatment in neonatal HI 
[129]. Administration of melatonin to adult rats during 
hypothermia promotes tissue oxygenation and enhances the 
body's resistance to hypothermia [130]. However, this 
combination has only been tested in adult studies, and there 
is no experience in neonatal models. An extremely important 
issue here is that each pharmacologic compound directed at a 
specific molecular pathway has its own optimal dose and 
optimal point in post-ictal time to achieve its optimal 
neuroprotective effect. It will be a major challenge to define 
the optimal time of application for each individual 
intervention and to design the best schedule to let them act in 
concert.  
 Fig.  (2) shows the possibilities for combination therapy 
and the most optimal point of time to start a specific 
treatment modality. 
 Fig.  (3) shows the most important pharmacological 
agents investigated in experimental and clinical studies for 
treatment of reperfusion/reoxygenation injury to the neonatal 
brain after perinatal asphyxia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Possibilities for combination therapy and the potential optimal point of time to start a specific treatment modality. XO, free radicals 
and nNOS increase prenatally after hypoxia-ischemia and reach the peak immediately after reperfusion/reoxygenation. Then there is a quick 
decrease in these three kinds of factors during the first 6h after reperfusion/reoxygenation. However, there is a secondary increase of free 
radical formation 12h later. Cytokines, iNOS and apoptotic activity appear 3h after reperfusion/reoxygenation and gradually increase to the 
plateau at 6h. 12h after reperfusion/reoxygenation, the downregulation of trophic factors starts and is stabilized at 24h. Interventions of 
hypothermia/NOS-inhibitor/2-IB/anti-oxidants/Xenon should be started as early as possible, at least no later than 6h after 
reperfusion/reoxygenation. Interventions of anti-inflammation and anti-apoptosis should also start early and no later than 9h after 
reperfusion/reoxygenation. Trophic support with EPO and IGF-1 can be performed 12h after reperfusion/reoxygenation. Furthermore, stem 
cells are suggested to be carried out 24h later. EPO=erythropoietin; IGF-1=insuline-like growth factor 1; 2-IB=2-iminobiotin; NOS= nitric 
oxide synthase; nNOS= neuronal NOS; TAT-JBD= TAT coupled JNK binding domain; TAT-NBD=TAT-coupled NFB essential modulator 
binding domain; XO=xanthine-oxidase. 330    Current Neuropharmacology, 2010, Vol. 8, No. 4  Fan et al. 
CONCLUSIONS AND RECOMMENDATIONS 
  In conclusion, rapid progress in neuroprotective 
pharmacology has already provided us with a wide selection 
of pathways that could be targeted for treatment of perinatal 
HI-induced brain injury. Combination of therapies may lead 
to a larger neuroprotective effect on the brain than single 
compound treatment and this possibility should be pursued 
further.  
  Further research of promising pharmacologic inter- 
ventions should be intensively performed and major attention 
should be given to reducing side effects and toxicity so that 
more and more therapies can be carried from animal 
experiments to clinical trials. Recent findings indicating that 
gender differences in sensitivities to both HI injury and drug 
treatment should be taken into account [131] and gender-
specific therapies may provide more promising interventions 
for perinatal HI-induced brain injury. Finally, recent findings 
indicating that stimulation of endogenous repair mechanisms 
can have potent effects on both histological and behavioral 
are promising. These findings are especially important since 
repair mechanisms could be effectively activated even days 
to weeks after the insult. 
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